[
  {
    "ts": null,
    "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2024 Update",
    "summary": "GMOâs 13F portfolio increased to $31.91B in Q3 2024. Click here to read more about the holdings and trades of GMO Capital Portfolio.",
    "url": "https://finnhub.io/api/news?id=1f10612cc8dd076b517497a7701346c351e530bf49e662e6f9e4366aee31e2cd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731523255,
      "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q3 2024 Update",
      "id": 131336623,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "GMOâs 13F portfolio increased to $31.91B in Q3 2024. Click here to read more about the holdings and trades of GMO Capital Portfolio.",
      "url": "https://finnhub.io/api/news?id=1f10612cc8dd076b517497a7701346c351e530bf49e662e6f9e4366aee31e2cd"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=7b43a21f3743171f80b0a86684f9d3bb51f15d518d9d588827f54998c48ba352",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731515700,
      "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "id": 131414228,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=7b43a21f3743171f80b0a86684f9d3bb51f15d518d9d588827f54998c48ba352"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)",
    "summary": "Merck &amp; Co., Inc. (NYSE:MRK) UBS Global Healthcare Conference November 13, 2024 12:30 PM ETCompany ParticipantsJannie Oosthuizen - President of Human...",
    "url": "https://finnhub.io/api/news?id=b2412fb57fe99b026a86d2236a15343876afb5eaba10e3491ef7cbecb85db1d4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731513787,
      "headline": "Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript)",
      "id": 131333188,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck &amp; Co., Inc. (NYSE:MRK) UBS Global Healthcare Conference November 13, 2024 12:30 PM ETCompany ParticipantsJannie Oosthuizen - President of Human...",
      "url": "https://finnhub.io/api/news?id=b2412fb57fe99b026a86d2236a15343876afb5eaba10e3491ef7cbecb85db1d4"
    }
  },
  {
    "ts": null,
    "headline": "Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial",
    "summary": "AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in adults with neurofibromatosis type 1 – NF1 – who have symptomatic, inoperable plexiform neurofibromas, or PN. Topline results showed that Koselugo demonstrated a statistically significant and clinically meaningful improvement in objective response rate, the study’s primary endpoint, versus placebo, in these adult patients. Neurofibromatosis type 1 is a rare,",
    "url": "https://finnhub.io/api/news?id=86bd1ffa814a539dd6abfdb432a96eaf352a2e44e6920a5d068342be95851b9d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731498980,
      "headline": "Merck and AstraZeneca announce results of Koselugo in neurofibromatosis trial",
      "id": 131325382,
      "image": "https://media.zenfs.com/en/tipranks_452/060c7819ab2e6aac03de78d24e089052",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AstraZeneca (AZN) Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in adults with neurofibromatosis type 1 – NF1 – who have symptomatic, inoperable plexiform neurofibromas, or PN. Topline results showed that Koselugo demonstrated a statistically significant and clinically meaningful improvement in objective response rate, the study’s primary endpoint, versus placebo, in these adult patients. Neurofibromatosis type 1 is a rare,",
      "url": "https://finnhub.io/api/news?id=86bd1ffa814a539dd6abfdb432a96eaf352a2e44e6920a5d068342be95851b9d"
    }
  },
  {
    "ts": null,
    "headline": "MSD and AstraZeneca report positive topline data from Koselugo trial for NF1",
    "summary": "Participants were enrolled from 13 countries across Australia, Asia, South America, Europe, and the US.",
    "url": "https://finnhub.io/api/news?id=f1678c112245c02dd3ef64e8b96a48a17a3874559b801d0e2820fddb79d3589f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731493561,
      "headline": "MSD and AstraZeneca report positive topline data from Koselugo trial for NF1",
      "id": 131322038,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/11/CTA-1-MSDAstra-Shutterstock_2134114319.jpg",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Participants were enrolled from 13 countries across Australia, Asia, South America, Europe, and the US.",
      "url": "https://finnhub.io/api/news?id=f1678c112245c02dd3ef64e8b96a48a17a3874559b801d0e2820fddb79d3589f"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. - KOSELUGO Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults with Neurofibromatosis Type 1",
    "summary": "RAHWAY - Alexion, AstraZeneca Rare Disease and Merck , known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 KOMET trial, which is the...",
    "url": "https://finnhub.io/api/news?id=f917d05f25d254802302b74f91fc9e3269761e5a562bf456814a74edc01bc999",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731493122,
      "headline": "Merck & Co., Inc. - KOSELUGO Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults with Neurofibromatosis Type 1",
      "id": 131325273,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY - Alexion, AstraZeneca Rare Disease and Merck , known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 KOMET trial, which is the...",
      "url": "https://finnhub.io/api/news?id=f917d05f25d254802302b74f91fc9e3269761e5a562bf456814a74edc01bc999"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Present New Data From GARDASIL9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference 2024",
    "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that new clinical and real-world data for the company's 9-valent Human Papillomavirus vaccine, GARDASIL 9 ,...",
    "url": "https://finnhub.io/api/news?id=a7f291ef05ae3d7531bc594f75c6ca2b92d903cdf28eb012eadac7d816410660",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731493119,
      "headline": "Merck to Present New Data From GARDASIL9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference 2024",
      "id": 131325275,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced that new clinical and real-world data for the company's 9-valent Human Papillomavirus vaccine, GARDASIL 9 ,...",
      "url": "https://finnhub.io/api/news?id=a7f291ef05ae3d7531bc594f75c6ca2b92d903cdf28eb012eadac7d816410660"
    }
  },
  {
    "ts": null,
    "headline": "Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)",
    "summary": "Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth. Check out why I upgraded OGN stock to buy from hold.",
    "url": "https://finnhub.io/api/news?id=45b4f472c138c712197326acf1cb9a3901804540f229dae4e0e0d85bab1ff0df",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731486600,
      "headline": "Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)",
      "id": 131323898,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2164256928/image_2164256928.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth. Check out why I upgraded OGN stock to buy from hold.",
      "url": "https://finnhub.io/api/news?id=45b4f472c138c712197326acf1cb9a3901804540f229dae4e0e0d85bab1ff0df"
    }
  },
  {
    "ts": null,
    "headline": "Shelton Equity Income Strategy Q3 2024 Commentary",
    "summary": "Following a rocky start to the quarter, the market found its footing and rallied to new record highs to finish the quarter strong. Click here to read the full letter.",
    "url": "https://finnhub.io/api/news?id=cbbee69972998f2c1f0ce58514838c096da5a9ebbc03d2948698caa10a65e7b0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731466200,
      "headline": "Shelton Equity Income Strategy Q3 2024 Commentary",
      "id": 131319327,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2083917031/image_2083917031.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Following a rocky start to the quarter, the market found its footing and rallied to new record highs to finish the quarter strong. Click here to read the full letter. ",
      "url": "https://finnhub.io/api/news?id=cbbee69972998f2c1f0ce58514838c096da5a9ebbc03d2948698caa10a65e7b0"
    }
  }
]